C - Chemistry – Metallurgy – 07 – C
Patent
C - Chemistry, Metallurgy
07
C
C07C 233/05 (2006.01) A61K 31/44 (2006.01) C07C 255/60 (2006.01) C07C 275/24 (2006.01) C07D 213/02 (2006.01) C07D 213/64 (2006.01)
Patent
CA 2510785
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
L'invention concerne de nouveaux composés représentés par la formule (I) antagonistes et/ou agonistes inverses du récepteur cannabinoïde-1 (CB1) et utilisés pour traiter, prévenir et supprimer des maladies induites par ledit récepteur CB1. Les composés de l'invention sont utilisés comme médicaments agissant de manière centrale dans le traitement de la psychose, des déficits de la mémoire, des troubles cognitifs, de la migraine, des neuropathies, des troubles neuro-inflammatoires comprenant la sclérose en plaques, le syndrome de Guillain-Barré, les séquelles inflammatoires de l'encéphalite virale, les accidents cérébro-vasculaires, les traumatismes crâniens, les troubles de l'anxiété, le stress, l'épilepsie, la maladie de Parkinson, les troubles du déplacement et la schizophrénie. On utilise également lesdits composés pour traiter les troubles dus à l'abus de substances, les troubles de l'obésité ou de l'alimentation, ainsi que l'asthme, la constipation, la pseudo-obstruction intestinale chronique, et la cirrhose du foie.
Doss George
Hagmann William K.
Kumar Sanjeev
Lin Linus S.
Yin Wenji
Merck & Co. Inc.
Merck Sharp & Dohme Corp.
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
LandOfFree
Substituted amides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted amides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted amides will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1427773